Reports

Sale

Critical Care Antiarrhythmic Drugs Market

Global Critical Care Antiarrhythmic Drugs Market Size, Share: By Drug Class: Beta Blockers, Calcium Chain Blockers, Sodium Channel Blockers, Potassium Channel Blockers, Others; By Diseases Type; By Route of Administration; By Treatment Channel; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Critical Care Antiarrhythmic Drugs Market Outlook

The global market value in 2023 was USD 1061.49 million, driven rising demand for advanced healthcare facilities across the globe. The critical care antiarrhythmic drugs market size is anticipated to grow at a CAGR of 5.6% during the forecast period of 2024-2032 to achieve a value of USD 1733.37 billion by 2032.

 

Global Critical Care Antiarrhythmic Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

North America to be a Significant Regional Market for Critical Care Antiarrhythmic Drugs

North America represents a significant share of the critical care antiarrhythmic industry due to advancements in cutting-edge medical research and development (R&D) activities. The introduction of favourable reimbursement policies by governments and advanced health care infrastructure in the region is expected to surge the demand for critical care antiarrhythmic medicines and bolster the market growth in the forecast period. As several government-funded organisations, academic institutions, and private entities are intensely initiating clinical trials and drug development activities for effective treatment of complicated cardiac disorders, the market is poised to grow robustly in the coming years.

Europe is witnessing rapid growth owing to the increasing geriatric population with various health-related issues. The introduction of various favourable initiatives by governments to bolster the accessibility of healthcare is propelling the market growth. Further, the rising awareness regarding atrial fibrillation and associated heart conditions is anticipated to propel the regional market growth, which is estimated to significantly contribute to the growth of the overall industry.

 

Critical Care Antiarrhythmic Drugs: Market Segmentation

Critical care antiarrhythmic drugs refer to medications that are used in the treatment of arrhythmias during serious cardiovascular issues. They follow up on the heart's electrical conduction system trying to keep up the sinus beat. Calcium channel blockers, anti-adrenergic agents, antiarrhythmic agents, diuretic agents, and angiotensin-converting enzyme (ACE) inhibitors are some of the medications used to treat cardiac problems. Antiarrhythmic medications work by inhibiting aberrant cardiac rhythms caused by atrial flutter, atrial and ventricular fibrillation, and other irregular electrical activity of the heart.

 

Global Critical Care Antiarrhythmic Drugs Market By Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

By drug class, the market is divided into:

  • Bovine
  • Human
  • Recombinant
  • Others

Based on end-use, the market includes:

  • Hospitals
  • Diagnostics
  • Others

The EMR report looks into the regional markets of critical care antiarrhythmic drugs like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Global Critical Care Antiarrhythmic Drugs Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Increasing Regulatory Approvals of Novel Drug Formulations Boosting the Market Growth of Critical Care Antiarrhythmic Drugs

The growth of the critical care antiarrhythmic drugs industry can be attributed to the increasing approvals and active support for novel medication formulations for antiarrhythmic treatment by regulatory agencies. This, in turn, is encouraging major companies to innovate and bolster production, allowing them to meet the growing demand for effective cardiac treatments, hence driving the market growth. Moreover, the increasing prevalence of cardiovascular diseases in both developed and developing countries is expected to fuel the antiarrhythmic drugs industry in the forecast period. With the growing focus on heart health, the demand for critical care antiarrhythmic drugs is increasing, hence driving the market growth. The surging research and development (R&D) activities in drug discovery is anticipated to provide further impetus to the market growth in the coming years.

 

Key Industry Players in the Global Critical Care Antiarrhythmic Drugs Market

The report gives a detailed analysis of the following key players in the global critical care antiarrhythmic drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Pfizer
  • GlaxoSmithKline plc
  • Sanofi
  • Mylan N.V.
  • Upsher-Smith Laboratories LLC
  • Novartis AG
  • Mayne Pharma
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Diseases Type
  • Route of Administration
  • Treatment Channel
  • End User
  • Distribution Channel
  • Region
Breakup by Drug Class
  • Beta Blockers
  • Calcium Chain Blockers
  • Sodium Channel Blockers
  • Potassium Channel Blockers
  • Others
Breakup by Diseases Type
  • Supraventricular Arrhythmias
  • Ventricular Arrhythmias
  • Others
Breakup by Route of Administration
  • Oral
  • Parentals
  • Others
Breakup by Treatment Channel
  • Public
  • Private
Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Lupin
  • GSK Plc.
  • Glenmark Pharmaceuticals Inc.
  • Amneal Pharmaceuticals
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Arrhythmias Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Arrhythmias Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Arrhythmia Epidemiology (2016-2031)
    5.3    Europe Arrhythmia Epidemiology (2016-2031)
    5.4    Asia-Pacific Arrhythmia Epidemiology (2016-2031)
    5.5    Latin America Arrhythmia Epidemiology (2016-2031)
    5.6    Middle East & Africa Arrhythmia Epidemiology (2016-2031)
6    Global Critical Care Antiarrhythmic Drugs Market Overview 
    6.1    Global Critical Care Antiarrhythmic Drugs Market Historical Value (2017-2023) 
    6.2    Global Critical Care Antiarrhythmic Drugs Market Forecast Value (2024-2032)
7    Global Critical Care Antiarrhythmic Drugs Market Landscape
    7.1    Critical Care Antiarrhythmic Drugs: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Critical Care Antiarrhythmic Drugs: Product Landscape
        7.2.1    Analysis by Drug Class
        7.2.2    Analysis by Disease Type
        7.2.3    Analysis by Route of Administration
8    Critical Care Antiarrhythmic Drugs Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Critical Care Antiarrhythmic Drugs Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Critical Care Antiarrhythmic Drugs Market Segmentation
    11.1    Global Critical Care Antiarrhythmic Drugs Market by Drug Class
        11.1.1    Market Overview
        11.1.2    Beta Blockers
        11.1.3    Calcium Chain Blockers
        11.1.4    Sodium Channel Blockers
        11.1.5    Potassium Channel Blockers
        11.1.6    Others
    11.2    Global Critical Care Antiarrhythmic Drugs Market by Diseases Type
        11.2.1    Market Overview
        11.2.2    Supraventricular Arrhythmias
        11.2.3    Ventricular Arrhythmias
        11.2.4    Others
    11.3    Global Critical Care Antiarrhythmic Drugs Market by Route of Administration
        11.3.1    Market Overview
        11.3.2    Oral
            11.3.2.1    Tablets
            11.3.2.2    Capsules
        11.3.3    Parentals
            11.3.3.1    Intravascular 
            11.3.3.2    Intramuscular
        11.3.4    Others
    11.4    Global Critical Care Antiarrhythmic Drugs Market by Treatment Channel
        11.4.1    Market Overview
        11.4.2    Public
        11.4.3    Private
    11.5    Global Critical Care Antiarrhythmic Drugs Market by End User
        11.5.1    Market Overview
        11.5.2    Hospitals
        11.5.3    Specialty Clinics
        11.5.4    Homecare Settings
        11.5.5    Others
    11.6    Global Critical Care Antiarrhythmic Drugs Market by Distribution Channel
        11.6.1    Market Overview
        11.6.2    Hospital Pharmacy
        11.6.3    Retail Pharmacy
        11.6.4    Online Pharmacy
        11.6.5    Others
    11.7    Global Critical Care Antiarrhythmic Drugs Market by Region
        11.7.1    Market Overview
        11.7.2    North America
        11.7.3    Europe 
        11.7.4    Asia Pacific
        11.7.5    Latin America
        11.7.6    Middle East and Africa
12    North America Critical Care Antiarrhythmic Drugs Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Critical Care Antiarrhythmic Drugs Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Critical Care Antiarrhythmic Drugs Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Critical Care Antiarrhythmic Drugs Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Critical Care Antiarrhythmic Drugs Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
    17.1.1    US FDA
    17.1.2    EU EMA
    17.1.3    INDIA CDSCO
    17.1.4    JAPAN PMDA
    17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    F. Hoffmann-La Roche Ltd.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Fresenius Kabi AG
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Bayer AG
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Sun Pharmaceutical Industries Ltd.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Novartis AG
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Mylan N.V.
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Teva Pharmaceutical Industries Ltd.
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Pfizer Inc.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Lupin
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    GSK Plc.
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Glenmark Pharmaceuticals Inc.
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    Amneal Pharmaceuticals
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
24    Critical Care Antiarrhythmic Drugs Market- Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global market for Critical Care Antiarrhythmic Drugs reached a value of USD 1061.49 million.

The market is anticipated to grow at a CAGR of 5.6% during the forecast period of 2024-2032 to reach a value of USD 1733.37 million by 2032.

The market is being aided by the expansion of health care infrastructure, the increasing geriatric population, and the surging clinical trials and drug development activities for effective treatment of complicated cardiac disorders.

The increasing approval of novel drugs, the rising prevalence of cardiovascular diseases, and the surging research and development (R&D) activities in drug discovery are estimated to propel the growth of the market.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The major drug classes of critical care antiarrhythmic drugs are bovine, human, and recombinant, among others.

The significant disease types of antiarrhythmic drugs in the market are hospitals and diagnostics, among others.

The major players in the industry are Pfizer, GlaxoSmithKline plc, Sanofi, Mylan N.V., Upsher-Smith Laboratories LLC, Novartis AG, and Mayne Pharma, among others.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER